For Patients:
Find out more about clinical trials, why they are done, how you can join a trial and what you can expect if you decide to take part in a trial.
Learn more about clinical trials

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

Description
Main study: This is an open-label, phase 2 study that aims to evaluate the efficacy and safety/tolerability of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma and primary or secondary resistance to PD-(L)1 inhibition.

View Eligibility & Trial Details >
https://www.uhn.ca/PrincessMargaret/Education/Continuing_Education_Programs/Pages/continuing_education_programs.aspx
Last reviewed:
Last modified: 8/16/2023 10:09 AM
Back to Top